Item 1.01 Entry into a Material Definitive Agreement
On November 7, 2022, Lannett Company, Inc. (the "Company") entered into a
Sub-License Agreement with Ypsomed AG (the "Agreement"), the supplier of the pen
injector device to be used in connection with the biosimilar insulin glargine
and biosimilar insulin aspart products under development by the Company and its
collaboration partner, HEC Pharma company ("Partner").
The Agreement provides, among other things, that the Company shall receive a
sub-license in exchange for its financial contribution to a licensing
arrangement between Ypsomed and Sanofi-Aventis Deutschland GmbH, holder of
various patents relating to the pen injector device. The sub-license shall
provide the Company and Partner freedom to operate and a covenant not to sue for
the final assembly, registration, use, sale and offer for sale of the pen
injector device used in connection with Company's insulin products in the
Territories (as defined in the Ypsomed supply agreement, including the USA). The
financial terms of the Agreement are confidential.
The Company expects to file the Agreement (in redacted form) as an exhibit to
its Quarterly Report on Form 10-Q for the fiscal quarter ending December 31,
2022. The description of the Agreement contained herein does not purport to be
complete and is qualified in its entirety by reference to the full text of the
Agreement when filed.
© Edgar Online, source Glimpses
LANNETT COMPANY, INC. 
